Syntis
Science & Engineering · Health Care
$46.7Mtotal raised · 10 rounds on record
$25Mlatest round · Venture round · Jun 2025 · 16 mo ago
$3.8Mgrants · 7 grants · CORDIS
50+team · employees, estimated range
Overview
Syntis Bio is unlocking the full therapeutic potential of the small intestine. Revolutionizing oral therapy for obesity, rare diseases, & beyond.
Funding and backers
Total raised
$46.7M
10 rounds on record
Latest round
$25M
Venture round · Jun 2025 · 16 mo ago
Team
51-200
employees, estimated range
Grants
$3.8M
7 grants · CORDIS
The money's age
Due for its next round
16 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 9
New executive Syntis Bio Strengthens Leadership Team with Appointment of Matt Dallas as Chief Financial Officer · syntis.bio
Sep 17, 2025
Won a grant $347k · CORDIS
Sep 10, 2025
Won a grant $344k · CORDIS
Sep 1, 2025
Won a grant $916k · CORDIS
Aug 1, 2025
Won a grant $325k · CORDIS
May 1, 2025
Won a grant $1.2M · CORDIS
Dec 30, 2024
Raised a round Venture round $6.3M · SEC Form D
Sep 15, 2024
Won a grant $323k · CORDIS
Jun 11, 2024
Launched Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small In… · syntis.bio
May 1, 2024
Won a grant $349k · CORDIS
Aug 17, 2022
Board appointment Carlo Traverso, Director · SEC Form D
Aug 3, 2022
Raised a round Venture round $15.4M · SEC Form D
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2025 | $347k | — | CORDIS |
| Grant | Sep 2025 | $344k | — | CORDIS |
| Grant | Sep 2025 | $916k | — | CORDIS |
| Grant | Aug 2025 | $325k | — | CORDIS |
| Venture round | Jun 2025 | $25M | — | SEC Form D |
| Grant | May 2025 | $1.2M | — | CORDIS |
| Venture round | Dec 2024 | $6.3M | — | SEC Form D |
| Grant | Sep 2024 | $323k | — | CORDIS |
| Grant | May 2024 | $349k | — | CORDIS |
| Venture round | Aug 2022 | $15.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | SYNTIS BIO, INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Rahul DhandaExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Pioneering a Synapse Protecting Oral Therapy. Our Mission.
Unlock the potential of a Whole Genome Sequencing Test with Inocras. Transforming diagnosis and treatment for cancer and rare diseases.
Unlocking the Therapeutic Potential of Precision Ophthalmology. Eye2Gene is an AI-powered precision ophthalmology platform combining…
Innovation and effectiveness for the treatment of rare and ultra-rare diseases.
Explore the Kyntra Bio site to learn about our oncology and rare disease therapies, pipeline highlights, clinical trials, culture, and…
... Search Here .... Unleash the Potential of Every Agent with Rainmaker's AI.
Visa sponsorship
1
H-1B filings in 12 months
$113k
Median offered salary
0
Open roles in United States
Who they sponsor
Medical scientists
1
In the register as Syntis Bio, Inc., Boston, MA
Other sponsors in the same field
Pheast Therapeutics 
Aegis Sciences Corporation 
Emulate 
Fount Bio
Alert me
US Department of Labor · latest filing Mar 13, 2026 · Visa details by country
Financials
Total raised
$50.5M
Latest round
Grant
Funding rounds
10
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2025 | $347k | Details |
| Grant | 2025 | $344k | Details |
| Grant | 2025 | $916k | Details |
| Grant | 2025 | $325k | Details |
| Venture - Series Unknown | 2025 | $25M | Details |
| Grant | 2025 | $1.2M | Details |
| Venture - Series Unknown | 2024 | $6.3M | Details |
| Grant | 2024 | $323k | Details |
| Grant | 2024 | $349k | Details |
| Venture - Series Unknown | 2022 | $15.4M | Details |
People
Rahul Dhanda
Executive Officer, Director
Chenny Zhang
Director
Martin Madaus
Director
Carlo Giovanni Traverso
Director
Robert Langer
Director
Teymour Boutros-Ghali
Director
Michael Nannizzi
Director
Carlo Traverso
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Roche, Viking, and Syntis showcase obesity drug candidates
A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
Read more
Report
Syntis Bio Reports Phase 1/1b Results Demonstrating Weight-Loss and Satiety Hormone Modulation with Oral SYNT-101 in Patients with Obesity
28-Day multiple ascending dose (MAD) data demonstrates placebo-adjusted weight loss and replicates mechanistic similarity to bariatric surgery as first observed in the single ascending dose (SAD) study SYNT-101 was well tolerated across all doses in the 2
Read more
Report
Syntis Bio Reports Phase 1/1b Results Demonstrating Weight-Loss and Satiety Hormone Modulation with Oral SYNT-101 in Patients with Obesity
BOSTON, September 15, 2026--Syntis Bio, Inc., a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced results from its 28-day multiple ascending dose (MAD) portion of its Pha
Read more
Report
Syntis Bio Reports Phase 1/1b Results Demonstrating Weight-Loss and Satiety Hormone Modulation with Oral SYNT-101 in Patients with Obesity
Read more
Report
Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity Treatment
SYNT-101 was well tolerated across all doses with no related GI adverse events, no serious adverse events, and no discontinuations Data confirm SYNT-101's intended mechanism of nutrient redirection, with reduced glucose absorption and favorable changes in
Read more
Report
Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity Treatment
BOSTON, July 16, 2026--Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced initial safety, tolerability, and pharmacodynamic data from the single ascendi
Read more
Report
Syntis Bio Strengthens Leadership Team with Appointment of Matt Dallas as Chief Financial Officer
BOSTON, June 9, 2026 - Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced the appointment of Matthew Dallas as Chief Financial Officer, who brings more
Read more
Report
Syntis Bio Strengthens Leadership Team with Appointment of Matt Dallas as Chief Financial Officer
Read more
Report
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions
David Rosenbaum, Ph.D., joins as Chief Development Officer Christo Shalish joins as Chief Business Officer BOSTON, March 3, 2026 - Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the sma
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston
United States
HQ
Contact Us
50-200 est. staff
135 Morrissey Boulevard Ste 101A, Boston, MA 02125